A Narrative Review; Relation of Coronavirus Disease 2019 (COVID-19) with Several Hematological Disorders

Context: It's crucial to monitor hematologic biomarkers in patients with coronavirus disease 2019 (COVID-19) to identify abnormalities and guide treatment decisions. These biomarkers provide valuable information about the severity of the disease and assist healthcare providers in making informed decisions about patient care. Evidence Acquisition: The present study reviewed the most recent literature on hematologic biomarker abnormalities in patients with COVID-19 and considered their clinical significance. Results: Various abnormalities were observed in hematologic biomarkers, including prothrombin time (PT), partial thromboplastin time (PTT), red blood cell indices, interferon regulatory factor (IRF-7), and white blood cell (WBC) count. Notably, significant lymphocytopenia, thrombocytopenia, and leukocytosis were reported in patients with severe and fatal COVID-19 compared to those with non-severe disease and survivors. Conclusions: Hematologic biomarkers play a crucial role in understanding COVID-19 pathogenesis and guiding clinical management. Utilizing these markers allows clinicians to assess disease severity, predict prognosis, and tailor treatment strategies to improve patient outcomes. Continued research in this area is essential to fully realize the potential of hematologic biomarkers for COVID-19 management.